{"schema_version":"secwatch.filing_event.v1","accession":"0001999480-26-000011","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2026-05-13T11:04:01+00:00","discovered_at":"2026-05-13T11:05:00.322441+00:00","generated_at":"2026-05-13T11:07:47.775468+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alto Neuroscience Q1 net loss $26.2M; initiates Phase 2b trial for ALTO-207 in TRD","bullets":["Net loss of $26.2M for Q1 2026 vs $15.2M in Q1 2025; R&D expenses rose to $20.3M.","Cash and equivalents of $264.2M as of March 31, 2026, up from $177.0M after $120M PIPE closed in March.","Phase 2b trial of ALTO-207 in treatment-resistant depression (TRD) initiated; topline data expected 2H 2027.","ALTO-101 Phase 2 POC trial missed primary endpoint (theta-ITC) but showed significant EEG biomarker effects and attention improvement.","ALTO-300 and ALTO-100 Phase 2b topline data readouts delayed to 1H 2027 and mid-2027, respectively, due to enhanced patient eligibility review."],"urls":{"canonical":"https://secwatch.observer/filing/0001999480-26-000011","json":"https://secwatch.observer/filing/0001999480-26-000011.json","markdown":"https://secwatch.observer/filing/0001999480-26-000011.md","text":"https://secwatch.observer/filing/0001999480-26-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000199948026000011/0001999480-26-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000199948026000011/alto-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T11:07:47.775468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dec749001fe9675201f58ac210d0b8d9b2c8ac60","claim":"Alto Neuroscience, Inc. reported financial results for the quarter ended March 31, 2026.","evidence_excerpt":"On May 13, 2026, Alto Neuroscience, Inc. (the “Company”) reported financial results for the fiscal quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948026000011/0001999480-26-000011-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}